Arecor on Investor Meet Company Platform

RNS Number : 4464J

Arecor Therapeutics PLC

27 April 2022

 

Arecor Therapeutics plc

("Arecor" or the "Group")

Arecor to present on Investor Meet Company Platform

Cambridge, UK, 27 April 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer and Susan Lowther, Chief Financial Officer will be providing a live presentation relating to the Group's recently announced Year End Results for the year ended 31 December 2021 via the Investor Meet Company platform, on Thursday 5 May 2022 at 10:00am BST.

The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am BST on Wednesday 4 May, or at any time during the live presentation.

To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit: https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor . Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: [phone] Email: [e-mail]
Susan Lowther, Chief Financial Officer	Tel: [phone] Email: [e-mail]
Mo Noonan, Communications	Tel: [phone] Email: [e-mail]
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: [phone]
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: [phone] Email: [e-mail]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™ , we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio . 

For further details please see our website, www.arecor.com

 

END

 

 

MSCUNAKRUSUSUAR